Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
03
2022
accepted:
07
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
HBV-associated decompensated cirrhosis (HBV-DeCi) is attracting considerable attention due to disease acceleration and substantial mortality. Macrophages regulate the fibrotic process in DeCi. Soluble CD206 (sCD206) is primarily expressed by macrophages. We aimed to investigate whether sCD206 predicts mortality in patients with HBV-DeCi. A total of 382 patients were enrolled between February 2020 and February 2021 and divided into nonsurviving and surviving groups according to 28-day, 3-month, and 6-month outcomes. Cox regression analysis was performed to confirm the independent prognostic factors of HBV-DeCi, and Kaplan-Meier analysis was performed to draw survival curves of sCD206. The predictive value of sCD206 was assessed at three time points according to the AUROC. The serum sCD206 level was significantly higher in deceased patients than surviving patients. Multivariate analysis showed that the level of sCD206 was related to an increased risk of 28-day, 3-month, and 6-month mortality (HR = 3.914, The macrophage-related marker serum sCD206 was associated with mortality in HBV-DeCi patients. High levels of serum sCD206 indicated a poor prognosis in these patients. Serum sCD206 has great predictive value for short-term and midterm mortality compared with the Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores.
Sections du résumé
Background
UNASSIGNED
HBV-associated decompensated cirrhosis (HBV-DeCi) is attracting considerable attention due to disease acceleration and substantial mortality. Macrophages regulate the fibrotic process in DeCi. Soluble CD206 (sCD206) is primarily expressed by macrophages. We aimed to investigate whether sCD206 predicts mortality in patients with HBV-DeCi.
Materials and Methods
UNASSIGNED
A total of 382 patients were enrolled between February 2020 and February 2021 and divided into nonsurviving and surviving groups according to 28-day, 3-month, and 6-month outcomes. Cox regression analysis was performed to confirm the independent prognostic factors of HBV-DeCi, and Kaplan-Meier analysis was performed to draw survival curves of sCD206. The predictive value of sCD206 was assessed at three time points according to the AUROC.
Results
UNASSIGNED
The serum sCD206 level was significantly higher in deceased patients than surviving patients. Multivariate analysis showed that the level of sCD206 was related to an increased risk of 28-day, 3-month, and 6-month mortality (HR = 3.914,
Conclusion
UNASSIGNED
The macrophage-related marker serum sCD206 was associated with mortality in HBV-DeCi patients. High levels of serum sCD206 indicated a poor prognosis in these patients. Serum sCD206 has great predictive value for short-term and midterm mortality compared with the Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores.
Identifiants
pubmed: 35664435
doi: 10.1155/2022/7881478
pmc: PMC9159836
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7881478Informations de copyright
Copyright © 2022 Yue Zhang et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Front Med (Lausanne). 2021 Jan 08;7:615599
pubmed: 33490096
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Nat Genet. 2017 May;49(5):795-800
pubmed: 28394349
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Clin Chem Lab Med. 2014 Mar;52(3):453-61
pubmed: 24114918
Liver Int. 2020 Feb;40 Suppl 1:22-26
pubmed: 32077612
PLoS One. 2017 Dec 13;12(12):e0189345
pubmed: 29236785
Lancet. 2021 Oct 9;398(10308):1359-1376
pubmed: 34543610
Aliment Pharmacol Ther. 2020 Aug;52(3):492-499
pubmed: 32573818
J Hepatol. 2014 Sep;61(3):642-59
pubmed: 25015420
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Semin Immunopathol. 2009 Sep;31(3):399-409
pubmed: 19468732
Sci Rep. 2021 Mar 15;11(1):5923
pubmed: 33723292
J Immunol. 2000 Nov 15;165(10):5428-34
pubmed: 11067894
Front Med (Lausanne). 2021 Jul 15;8:698502
pubmed: 34336902
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
J Leukoc Biol. 2019 Nov;106(5):1129-1138
pubmed: 31242338
J Hepatol. 2016 Apr;64(4):813-22
pubmed: 26639396
J Hepatol. 2014 May;60(5):1090-6
pubmed: 24412603
J Hepatol. 2014 Sep;61(3):660-71
pubmed: 24798624
J Hepatol. 2022 Jan;76(1):202-207
pubmed: 34157322
Front Med. 2017 Dec;11(4):490-501
pubmed: 29170919
Int Immunopharmacol. 2020 Sep;86:106732
pubmed: 32622200
Hepatology. 2003 Jul;38(1):258-66
pubmed: 12830009
J Leukoc Biol. 2015 Dec;98(6):1071-80
pubmed: 26216935
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Nat Rev Immunol. 2022 Jan;22(1):19-32
pubmed: 34002067
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Gastroenterol Hepatol. 2018 Feb;33(2):484-491
pubmed: 28618015